Advanced Prostate

Castrate Resistant

Metastatic

Hormone Naive

Non-Metastatic

1st Line
No prior AR
Targeting Agent

IRB# 1127
Phase II study of
cabazitaxel +
enzalutamide

2nd Line
Post-AR targeting Agent

IRB# 16294
Phase I Safety and
Tolerability of ZEN003694 w/
enzalutamide or
abiraterone acetate

Chemotherapy
Naive

IRB# 17864
Phase III Study of
Rucaparib versus
physician’s choice
for patients with
mCRPC associated
with Homologous
Recombination
Deficiency

Post Taxane-based
Chemotherapy

IRB# 16446
Phase I study of
niraparib + AR-
targeted therapies

Supportive
Care/Biomarker

IRB# 15921
INTERVAL: Intense
exercise for
survival among
men with mCRPC

IRB# 15944
Falls in Elderly
Men Taking
Enzalutamide

IRB# 16837
International
Registry for Men
with Advanced
Prostate Cancer

IRB# 19002
Lu-PSMA
radionuclide in
PSMA-Positive
mCRPC

New Trial Coming Soon

IRB# 17717
Degarelix,
apalutamide,
abiraterone
acetate in
biochemically
relapsed
prostate cancer

New Trial Coming Soon

IRB# 11296
Salvage radiation +
enzalutamide/pla
cbo for recurrent
prostate cancer

IRB# 9204:
Stand Up To
Cancer

IRB# 16294
Phase I Safety and
Tolerability of
ZEN003694 w/
enzalutamide or
abiraterone acetate

IRB# 19002
Lu-PSMA
radionuclide in
PSMA-Positive
mCRPC

IRB# 19002
Lu-PSMA
radionuclide in
PSMA-Positive
mCRPC

IRB# 11268
Salvage radiation +
enzalutamide/pla
cbo for recurrent
prostate cancer

IRB# 18231
Phase 1/2a Study of
CORT125281 and
enzalutamide

IRB# 19002
Lu-PSMA
radionuclide in
PSMA-Positive
mCRPC

IRB# 16446
Phase I study of
niraparib + AR-
targeted therapies

IRB# 15921
INTERVAL: Intense
exercise for
survival among
men with mCRPC

Supportive
Care/Biomarker

IRB# 15944
Falls in Elderly
Men Taking
Enzalutamide

IRB# 16837
International
Registry for Men
with Advanced
Prostate Cancer

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

2/1/2019